Literature DB >> 16647990

Primary nasal non-Hodgkin lymphomas presented initially as benign disease.

Dionysios E Kyrmizakis1, Jiannis K Hajiioannou, Anastasios V Koutsopoulos, Eleni Papadaki, Dimitrios Papadakis, John Bizakis, George Velegrakis.   

Abstract

BACKGROUND: Primary non-Hodgkin lymphomas (NHLs) of the sinonasal tract comprise a rare entity that constitutes 1.5% of all NHLs and 2.2% of extranodal lymphomas in the whites. Clinical diagnosis may be very challenging because of the variety and low specificity of the presenting symptoms and signs. METHODS-
RESULTS: We present three cases of NHLs, initially diagnosed as benign diseases. All three cases have been eventually correctly diagnosed and treated in our hospital between January 2000 and December 2003. The patients have been under close follow-up from 11 to 36 months after the initial treatment. One of them remains without clinical or radiological evidence of recurrence, whereas the two others died 11 and 16 months after the initial diagnosis.
CONCLUSION: It is important to underline that atypical or persistent symptoms of rhinosinusitis may represent the initial expression of a more serious condition such as deep fungal infection, vasculitis, lymphoma, or other malignancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647990     DOI: 10.1016/j.amjoto.2005.09.019

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  2 in total

1.  Primary sino-orbital peripheral T-cell lymphoma presenting as unilateral periorbital swelling: a case report.

Authors:  Ahmad Al Omari; Firas Al Zoubi; Mohammad M Alsalem; Khalil M Al-Salem; Hasan Mohidat
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

2.  Sinonasal natural killer/T-cell lymphoma presenting as pyrexia of unknown origin with nasal symptoms.

Authors:  Betsy K H Soon; Xin-Rong Lim; Deborah H L Ng; Ming-Yann Lim
Journal:  Singapore Med J       Date:  2014-07       Impact factor: 1.858

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.